HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RN909

a monoclonal antibody antagonist of the glucagon receptor

Also Known As:

PF-06293620

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Dell, Vanessa: 1 article (11/2018)
2.	Esteves, Brooke: 1 article (11/2018)
3.	Forgie, Alison: 1 article (11/2018)
4.	Garzone, Pamela D: 1 article (11/2018)
5.	Gumbiner, Barry: 1 article (11/2018)
6.	Joh, Tenshang: 1 article (11/2018)
7.	Udata, Chandrasekhar: 1 article (11/2018)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 11/01/2018 - "Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial." 11/01/2018 - "This first-in-human study assessed safety, immunogenicity, pharmacokinetics, and pharmacodynamics of RN909, a monoclonal antibody antagonist of the glucagon receptor, in type 2 diabetes (T2DM) subjects. "
2.	Diarrhea 11/01/2018 - "RN909 was well tolerated after single and multiple doses in T2DM subjects, with diarrhea and elevated LFTs the most frequent adverse events. "

Related Drugs and Biologics

1.	Glucagon Receptors (Glucagon Receptor)
2.	Monoclonal Antibodies